DXR: Daxor Corp Market Cap to Revenue Ratio

Symbol and logo of brand Daxor Corporation (DXR)

Daxor Corporation is developing ultra-precise BVA-100 systems and is preparing to release new analyzers. Capitalization is based on the sale of devices and consumables for heart failure therapy. Monitoring the company's P/S ratio clearly demonstrates the market valuation of revenue, where the 327.20 mark characterizes this parameter. Business stability is ensured by patents for blood measurements and strict FDA oversight.

Daxor Corp (DXR): P/S Multiple from 07/04/2022 to 11/14/2026

Metric breakdowns and analytics for Daxor Corporation (DXR)

- current quotes and average value forecast:
Market Price daxor.com|DXR - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Daxor Corp.|DXR - Enterprise Value
- business book valuation details:
Net Assets per Share Daxor|DXR - Book Capitalization|Market Cap to Net Assets Ratio daxor.com|DXR - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Daxor Corporation|DXR - Long-Term Debt to Equity|Short-Term Debt to Equity daxor.com|DXR - Company Total Debt|Debt to Net Assets Ratio Daxor Corp.|DXR - Company Long-Term Debts|Short-Term Debt Daxor|Critical Liquidity daxor.com
- net income and valuation ratios data:
DXR - Net Income|Projected Future Earnings Daxor Corporation|DXR - P/E Multiple|Market Cap to Projected Earnings daxor.com|DXR - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Daxor Corp.|DXR - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Daxor|DXR - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months daxor.com|DXR - Earnings per share growth in current year|Projected earnings per share growth rate for next year Daxor Corporation
- issuer revenue and sales details:
DXR - Company Sales|Company Projected Revenue Volume daxor.com|DXR - P/S Multiple|Market Cap to Projected Revenue Daxor Corp.
Summary company analytics:Daxor Corp, DXR
Signature product of daxor.com

Daxor Corporation (DXR) is developing a high-tech intensive care segment through the implementation of the BVA-100 system. Analyzing the price-to-sales ratio allows for an assessment of market capitalization relative to the issuer's actual cash inflows. This coefficient compares the market price of shares with actual sales volume, separating fundamental growth from speculative overheating. Rational use of this metric protects investors from overvalued assets during periods of hype-driven demand.

Competing companies

ABT - Price to Sales|P/S Multiple TMO (Thermo Fisher)|GEHC: Market Cap to Revenue Ratio|Mettler-Toledo International Inc. - P/S Multiple|Price-to-Revenue Coefficient Waters Technologies WAT|TECH: P/S Multiple|Market Cap to Revenue bruker.com|AZTA (Azenta) - P/S Multiple|P/S Multiple Varex Imaging Corp|Price-to-Revenue Ratio Semler Scientific Corp (SMLR)|Price-to-Revenue Ratio BFLY (Butterfly Corp)|Mesa Laboratories, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio QSI|Nano-X - P/S Multiple|Price to Sales Quanterix Corp.|908 Devices Corp (MASS) - Price-to-Revenue Ratio|Price-to-Revenue Multiple CapsoVision CV|Market Cap to Revenue MXCT|P/S Multiple Rapid Micro|P/S Multiple SEER|Price-to-Revenue Coefficient Hyperfine Inc|Price-to-Revenue Ratio FONAR Corp FONR|MDAI (spectral-ai.com) - Price-to-Sales Ratio|VIVS - Price-to-Revenue Ratio|aclarion.com (ACON) - Market Cap to Revenue|AKYA: P/S Multiple|Price to Sales ThermoGenesis Holdings, Inc. (THMO)|Price-to-Revenue Ratio Talis Biomedical Corp.|Market Cap to Revenue Ratio TTOO (T2 Biosystems Inc)